Optimizing the use of biologics for treating patients with rheumatoid arthritis

December 19, 2016

The use of biologics, which are generally made from human and/or animal materials, has significantly changed the management of rheumatoid arthritis over the last decade, becoming the cornerstone treatment for many patients. Because the arsenal of biologics for rheumatoid arthritis includes numerous monoclonal antibodies with various mechanisms of action, it can be challenging to optimize treatments for individuals.

A new review of the indicates that blood concentrations of biologics can vary from patient to patient and may correlate with therapeutic response. Therefore, the use of a 'one dose fits all' approach, mainly proposed by pharmaceutical companies, needs to be reassessed. In general, individualized doses of biologics should be implemented in clinical practice.

"Since their usage is spreading, the study of factors and covariates that could relevantly influence serum drug concentrations and exposure would be extremely useful to better understand and predict drugs' pharmacokinetic/pharmacodynamic behavior in advance," wrote the authors of the British Journal of Clinical Pharmacology review. "Moreover, the applicability of population pharmacokinetic and pharmacodynamic models in the clinical setting would allow us to select the suitable dose for specific patients at the same time a cost-efficient approach is considered."

Explore further: New test could predict arthritis drug failure in patients

More information: Is there potential for Therapeutic Drug Monitoring of Biologic Agents in Rheumatoid Arthritis? British Journal of Clinical Pharmacology. DOI: 10.1111/bcp.13192

Related Stories

New test could predict arthritis drug failure in patients

July 3, 2015

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. These findings ...

Biosimilar switching not suitable for all patients

June 9, 2016

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react ...

Recommended for you

High-fat, high-carb diet a cause of osteoarthritis

April 18, 2017

Saturated fat is a prime suspect in the onset of osteoarthritis after QUT scientists found it changed the composition of cartilage, particularly in the weight-bearing joints of the hip and knee.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.